Plain-English translation of NCT06526299 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called 177Lu-PSMA-617, which is a radioactive treatment designed to find and attack prostate cancer cells. The study is designed for men whose cancer has spread to other parts of the body and is no longer responding to hormone-blocking drugs. Researchers want to see if giving stronger or more frequent doses of this treatment can help patients whose tumors have low levels of a specific cancer marker.
Many men with advanced prostate cancer stop responding to standard hormone-blocking treatments, leaving them with limited options. This trial exists to find out whether this medication, given at higher intensity, can help patients whose cancer cells don't light up as brightly on imaging scans—a group that often doesn't respond as well to standard dosing.
You likely qualify if…
You likely don't qualify if…
You would receive the radioactive medication as intravenous infusions (into your vein) on specific days over about 5 months, with treatment cycles spaced a week apart at first, then 6 weeks apart. You'll have several imaging scans (PET/CT, SPECT/CT, CT or MRI, and bone scans) and blood tests throughout the study to see how you're responding. After treatment ends, you'll return for follow-up visits at 30 days and then every 12 weeks for up to 2 years to monitor your progress.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States